T. Hughes, M. Deininger, A. Hochhaus, et al., “Monitoring CML Patients Responding to Treatment with Tyrosine Kinase Inhibitors: Review and Recommendations for Harmonizing Current Methodology for Detecting BCR-ABL Transcripts and Kinase Domain Mutations and for Expressing Results,” Blood, Vol. 108, No. 1, 2006, pp. 28-37. doi:10.1182/blood-2006-01-0092

has been cited by the following article:

• TITLE: Impact of the Normalized Copy Number of BCR-ABL Transcript upon Diagnosis on Prognosis in CML Patients Treated with Imatinib-Mesylate

  AUTHORS: Christophe Martinaud, Aurélie Mayet, Sophie Bousquet, Nathalie Beaufils, Jean Gabert, Sophie Raynaud, Marie-Joelle Mozziconacci

  KEYWORDS: Chronic Myeloid Leukemia, RQ-PCR, Normalized Copy Number, BCR-ABL

  JOURNAL NAME: Open Journal of Blood Diseases, Vol.1 No.2, December 5, 2011

  ABSTRACT: Quantification of the BCR-ABL transcript is recommended to follow-up CML patients treated by imatinib mesylate (IM). Results are expressed as a normalized copy number (NCN) of BCR-ABL. We studied a cohort of 98 CML patients under IM as a first treatment and monitored by RQ-PCR after 12, 18 and 24 months according to the European LeukemiaNet recommendations. Our results support the hypothesis of an independent correlation between BCR-ABL NCN at diagnosis and major molecular response at 18 and 24 months in an inverse relationship. We also highlighted the possibility to use the NCN at diagnosis as a warning at diagnosis, and may be useful to identify patients who could benefit of a more rigorous follow-up.